Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.40 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12262114 | 0.84 | TYR (0.38) | TYRMEN1LMNATHRBBLM | |
| SCHEMBL9945903 | 0.82 | ERN1 (0.42) | TYRMEN1LMNATHRBBLM | |
| SCHEMBL30842456 | 0.80 | CA1 (0.39) | TYRTDP1ERN1ALDH1A1TSHR | |
| SCHEMBL12173269 | 0.79 | EIF4A3 (0.41) | EIF4A3LMNABLMTSHR | |
| SCHEMBL1806887 | 0.79 | TDP1 (0.47) | TYRMEN1LMNATHRBBLM | |
| SCHEMBL31306390 | 0.79 | TDP1 (0.47) | TYRMEN1LMNATHRBBLM | |
| SCHEMBL31306389 | 0.79 | TDP1 (0.47) | TYRMEN1LMNATHRBBLM | |
| SCHEMBL22484321 | 0.76 | EIF4A3 (0.31) | EIF4A3 | |
| SCHEMBL26229527 | 0.75 | GAA (0.38) | TYREIF4A3MEN1LMNAKMT2A | |
| SCHEMBL9945895 | 0.73 | TYR (0.39) | TYRMEN1LMNATHRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | TYR 2328/4885EIF4A3 2250/4885MEN1 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.